In high‐grade ovarian carcinoma, platinum‐sensitive tumor recurrence and acquired‐resistance derive from quiescent residual cancer cells that overexpress CRYAB, CEACAM6, and SOX2. Issue 3 (20th April 2022)

• Record Type: Journal Article
• Authors: du Manoir, Stanislas; Delpech, Hélène; Orsetti, Béatrice; Jacot, William; Pirot, Nelly; Noel, Jean; Colombo, Pierre‐Emmanuel; Sardet, Claude; Theillet, Charles
• Is Part Of: Journal of pathology. Volume 257:Issue 3(2022)
• Page Start: 367
• Page End: 378
• Publication Date: 2022-04-20
• Subjects: high‐grade ovarian carcinoma -- platinum‐sensitive recurrence -- residual cancer -- acquired resistance -- drug tolerant state; Pathology -- Periodicals; 616.07
• DOI: 10.1002/path.5896
• Languages: English
• ISSNs: 0022-3417

Abstract

Abstract: Most high‐grade ovarian carcinomas (HGOCs) are sensitive to carboplatin (CBP)‐based chemotherapy but frequently recur within 24 months. Recurrent tumors remain CBP‐sensitive and acquire resistance only after several treatment rounds. Recurrences arise from a small number of residual tumor cells not amenable to investigation in patients. We developed patient‐derived xenografts (PDXs) that allow the study of these different stages of CBP‐sensitive recurrence and acquisition of resistance. We generated PDX models from CBP‐sensitive and intrinsically resistant HGOC. PDXs were CBP‐ or mock‐treated and tumors were sampled, after treatment and at recurrence. We also isolated models with acquired‐resistance from CBP‐sensitive PDXs. Tumors were characterized at the histological and transcriptome levels. PDX models reproduced treatment response seen in the patients. CBP‐sensitive residual tumors contained nonproliferating tumor cell clusters embedded in a fibrotic mesh. In nontreated PDX tumors and treated CBP‐resistant tumors, fibrotic tissue was not prevalent. Residual tumors had marked differences in gene expression when compared to naïve and recurrent tumors, indicating downregulation of the cell cycle and proliferation and upregulation of interferon response and the epithelial–mesenchymal transition. This gene expression pattern resembled that described in embryonal diapause and 'drug‐tolerant persister' states. Residual and acquired‐resistance tumors share the overexpression of three genes: CEACAM6, CRYAB, and SOX2 . Immunostaining analysis showed strong CEACAM6, CRYAB, and SOX2 protein expression in CBP‐sensitive residual and acquired‐resistance PDX, thus confirming the RNA profiling results. In HGOC PDX, CBP‐sensitive recurrences arise from a small population of quiescent, drug‐tolerant, residual cells embedded in a fibrotic mesh. These cells overexpress CEACAM6, CRYAB, and SOX2, whose overexpression is also associated with acquired resistance and poor patient prognosis. CEACAM6, CRYAB, and SOX2 may thus serve as a biomarker to predict recurrence and emergence of resistant disease in CBP‐treated HGOC patients. © 2022 The Pathological Society of Great Britain and Ireland.